Table 1

Baseline characteristics of patients stratified according to presence of myocardial infarction and major bleeding

CharacteristicsNeitherMI onlyMB onlyBothP value
N27 10916401123232
Female sex6454 (23.8%)440 (26.8%)353 (31.4%)87 (37.5%)<0.001
Age, mean (SD)64.3 (11.2)66.3 (11.7)68.6 (11.1)67.7 (11.3)<0.001
Age >7513 044 (48.1%)921 (56.2%)723 (64.4%)148 (63.8%)<0.001
Tobacco use12 688 (46.8%)762 (46.5%)427 (38.0%)92 (39.7%)<0.001
Diabetes mellitus9357 (34.5%)686 (41.8%)519 (46.2%)133 (57.3%)<0.001
Hypertension17 037 (62.8%)1169 (71.3%)865 (77.0%)191 (82.3%)<0.001
Dyslipidaemia17 313 (63.9%)1042 (63.5%)691 (61.5%)149 (64.2%)0.46
Cerebrovascular disease2342 (8.6%)217 (13.2%)163 (14.5%)47 (20.3%)<0.001
Chronic obstructive pulmonary disease629 (2.3%)72 (4.4%)35 (3.1%)6 (2.6%)<0.001
Peripheral artery disease309 (1.1%)44 (2.7%)40 (3.6%)15 (6.5%)<0.001
Prior myocardial infarction3281 (12.1%)335 (20.4%)200 (17.8%)58 (25.0%)<0.001
Prior CABG407 (1.5%)41 (2.5%)19 (1.7%)4 (1.7%)0.017
Congestive heart failure1842 (6.8%)258 (15.7%)169 (15.0%)58 (25.0%)<0.001
Atrial fibrillation or flutter1228 (4.5%)124 (7.6%)105 (9.3%)20 (8.6%)<0.001
Chronic kidney disease (eGFR <60 mL/min/m2)4498 (16.6%)475 (29.0%)439 (39.1%)131 (56.5%)<0.001
Anaemia at baseline*7569 (27.9%)638 (38.9%)620 (55.2%)161 (69.4%)<0.001
History of cancer1246 (4.6%)81 (4.9%)105 (9.3%)18 (7.8%)<0.001
Acute coronary syndrome21 528 (79.4%)1406 (85.7%)899 (80.1%)202 (87.1%)<0.001
Number of epicardial arteries affected<0.001
 One vessel12 451 (45.9%)572 (34.9%)444 (39.5%)60 (25.9%)
 Two vessels9086 (33.5%)562 (34.3%)383 (34.1%)85 (36.6%)
 Three vessels5572 (20.6%)506 (30.9%)296 (26.4%)87 (37.5%)
Aspirin on discharge26 327 (97.1%)1611 (98.2%)1101 (98.0%)228 (98.3%)0.011
P2Y12 inhibitor on discharge26 766 (98.7%)1626 (99.1%)1105 (98.4%)230 (99.1%)0.31
Potent P2Y12 inhibitor on discharge†2995 (11.0%)140 (8.5%)95 (8.5%)16 (6.9%)<0.001
Anti-coagulation on discharge796 (2.9%)60 (3.7%)86 (7.7%)7 (3.0%)<0.001
Proton pump inhibitor on discharge13 209 (48.7%)800 (48.8%)668 (59.5%)124 (53.4%)<0.001
Duration of DAPT, median (IQR)365 (187–401)368 (174–505)365 (102–403)370 (150–535)<0.001
  • *Anaemia: haemoglobin <13 g/dL for men, <12 g/dL for women.

  • †Prasugrel or ticagrelor were considered as potent P2Y12 inhibitors.

  • CABG, coronary artery bypass grafting; DAPT, dual antiplatelet therapy; eGFR, estimated glomerular filtration rate; MB, major bleeding; MI, myocardial infarction.